By entering this website, you confirm that you are at least 21 years of age and that you are a qualified researcher or purchasing on behalf of a research institution.
All products sold by BioNex are for laboratory research purposes only. They are not intended for human or animal consumption, and no medical, therapeutic, or diagnostic use is expressed or implied.
You acknowledge that BioNex assumes no liability for misuse, misapplication, or unauthorized use of any product purchased from this website.
By clicking “I Agree,” you accept full responsibility for compliance with all applicable laws and regulations.
Your access is restricted because of your age.
$61.00
Form: Lyophilized Powder
Purity: >99%
Tesamorelin 10mg has been studied for its potential mechanism of action, posited to be similar to growth hormone-releasing hormones (GHRH) receptors located at the anterior pituitary gland, possibly leading to increased production and secretion of growth hormones. Growth hormones may act on several cells, including hepatocytes, stimulating the systemic synthesis of insulin-like growth factor-1 (IGF-1). In addition, growth hormone may also stimulate IGF-1 production locally, inside various tissues.
Tesamorelin appears to stimulate the release of growth hormone, and consequently IGF-1, by potentially interacting with the GHRH receptors in the anterior pituitary gland cells. When Tesamorelin interacts with the GHRH receptor, it is hypothesized that this interaction might alter the receptor’s structure, potentially initiating communication pathways within the cell. It is also theorized that Tesamorelin might enhance the production of cyclic adenosine monophosphate (cAMP) in certain cells, possibly through stimulation of adenylate cyclase, an enzyme that converts adenosine triphosphate (ATP) into cAMP.
Increased cAMP levels may lead to the activation of protein kinase A (PKA), an enzyme critical for transmitting signals within cells. Activated PKA may phosphorylate various target proteins, triggering a cascade of cellular responses. This stimulation of the GHRH receptor by Tesamorelin and the cAMP-PKA signaling pathway might promote the secretion and distribution of growth hormone (hGH) from somatotroph cells in the pituitary gland.
Research indicates this peptide may lead to an estimated 69% increase in overall growth hormone levels and a 55% increase in mean pulse area of growth hormone, while IGF-1 levels apparently surged by 122%.
Specific alterations at the N-terminus and C-terminus of the GHRH molecule in Tesamorelin enhance peptide stability and resistance to enzymatic deactivation. The C-terminus is modified with a trans-3-hexenoic acid group, and the N-terminus is acetylated (CH₃CO-), resulting in the chemical designation N-(trans-3-hexenoyl)-[Tyr1]hGRF(1–44)NH2 acetate.